Hims & Hers Health (HIMS): Growth Is Real, But Execution Matters
Hims & Hers is scaling fast, with Q2 revenue up 38% and subscribers up 19%, but profitability, leverage, and regulatory risk keep the story from being a simple growth call. The stock still earns a Buy, though investors need to watch cash flow and margin pressure closely.
Hims & Hers Health (HIMS) is a Buy, earning an overall grade of B- as subscriber growth, higher monetization, and international expansion continue to support the long-term story. Our fair value is $30, but the stock still demands disciplined execution because margins, cash flow, and regulatory exposure remain volatile.
Thesis
Hims & Hers Health (HIMS) has built a fast-growing consumer health platform, but the stock now requires continued execution rather than a simple growth story. Revenue reached $753.2M in Q2 2026, up 38% year over year, while subscribers increased 19% to 2.891 million. Management also raised full-year 2026 revenue guidance to $3.1B-$3.3B. Those are substantial growth figures.
The counterweight is profitability and balance-sheet risk. Q2 produced an $86.3M net loss, adjusted EBITDA fell to $60.3M from $82.2M a year earlier, gross margin declined to 64%, and quarterly free cash flow was negative $55.4M. Total debt stood at $1.38B at June 30, 2026, against $609.8M of cash. HIMS is expanding into branded weight-loss products, international markets, testosterone, peptides, and AI while absorbing the Eucalyptus acquisition. That creates a large runway, but also a demanding capital and regulatory workload.
The investment case rests on three facts: subscriber scale, category expansion, and a more integrated care platform. The valuation case rests on a fourth: the stock trades at 67.6x forward earnings and 2.6x enterprise value to revenue. For a moderate-risk investor with a medium-term horizon, the appropriate stance is Buy, but only with respect for the company's volatile earnings, leverage, regulatory exposure, and 2.5 beta.
Company Overview
HIMS is a consumer-first health and wellness platform founded in 2017 and headquartered in San Francisco. It connects customers with licensed healthcare professionals, supports consultations and follow-up care, provides prescription and non-prescription products, and offers laboratory testing. The company operates in the United States, United Kingdom, Canada, Germany, the Republic of Ireland, France, Spain, Australia, and other international markets.
The model combines digital customer acquisition, recurring treatment plans, clinical consultations, product fulfillment, and follow-up services. HIMS serves areas including sexual health, hair care, dermatology, mental health, weight loss, hormone health, and general wellness. The model is more durable than a one-time e-commerce transaction when customers remain on ongoing treatment plans.
▌Common Questions
Frequently asked questions
+Is HIMS stock a buy right now?
Yes, HIMS is a Buy right now, but it is a higher-risk Buy rather than a clean quality compounder. The case rests on 38% Q2 revenue growth, 19% subscriber growth, and expanding international scale, while investors must accept margin pressure, negative free cash flow, and regulatory uncertainty.
+What is HIMS's fair value?
Hims & Hers Health's fair value is $30. We arrive there by balancing the stock’s 67.6x forward earnings multiple and 2.6x EV/revenue against strong subscriber growth, a raised $3.1B-$3.3B revenue outlook, and the drag from lower gross margins, leverage, and cash burn.
+
▌The Daily Briefing · Free
A new stock idea, every evening.
One stock worth watching each weekday, plus the analysis behind it. Free, in your inbox.
The customer base reached 2.891 million at the end of Q2 2026, up from 2.439 million a year earlier. Monthly revenue per average subscriber rose to $92 from $76. That combination of subscriber growth and higher monetization is important: HIMS is not relying on customer additions alone to expand revenue.
Business Segment Deep Dive
HIMS reports its operating performance mainly through geography and company-wide customer metrics rather than a detailed public segment schedule. The United States generated $621.8M of Q2 2026 revenue, up 16% year over year. Rest-of-world revenue reached $131.4M, up more than 17-fold year over year, helped by the Eucalyptus acquisition in June.
International expansion is now a material part of the strategy. Management said the United Kingdom, Australia, and Germany each generated more than $100M of annualized revenue, while Canada was progressing toward that threshold. Eucalyptus contributed approximately $40M of Q2 revenue and expanded HIMS into Europe, Australia, and Japan.
Within the United States, weight loss and sexual health are strategic anchor categories because they attract large audiences and create cross-sell opportunities. HIMS also identified low testosterone as a fast-growing specialty. Management expects testosterone to become its sixth U.S. specialty with a $100M annual revenue run rate.
The segment mix is changing the financial profile. Branded weight-loss products and international revenue carry lower gross margins than HIMS historically achieved. Q2 gross margin fell to 64% from 76% a year earlier, although adjusted EBITDA remained positive at $60.3M.
Get AI research on any stock
Instant reports, daily intelligence, and an AI analyst in your pocket.
Weight loss is the flagship growth engine because it combines high consumer demand, recurring treatment, laboratory testing, and opportunities to introduce customers to additional specialties. In March 2026, HIMS shifted its U.S. weight-loss strategy toward branded GLP-1 medications while keeping compounded offerings at a limited scale. In Q2, management said the broader branded assortment helped accelerate growth.
The economics are more complicated than the revenue growth suggests. HIMS said the move toward branded products created revenue-recognition headwinds through a monthly cadence and lowered gross margin. Working-capital needs also contributed to negative Q2 operating cash flow of $35.9M. The product can expand the customer base, but its contribution must eventually support stronger cash conversion.
HIMS also launched injectable and oral testosterone offerings in October 2026. Management described testosterone as scaling faster than any specialty outside weight loss during its first three quarters. The combination of at-home blood collection, longitudinal tracking, and provider-guided treatment gives the product a recurring-care structure rather than a simple product-sale structure.
The next product layer is peptides. HIMS said it was conducting validation and stability testing for APIs associated with six peptides discussed at a recent FDA advisory hearing. It also planned access to permitted peptides such as sermorelin, glutathione, and NAD+. This opportunity is meaningful, but it is directly tied to regulatory decisions and supply-chain execution.
Innovation & Competitive Advantage
HIMS is positioning AI as an operating system for care rather than a customer-service add-on. In the Q2 2026 transcript, management said the new Hers weight-loss care experience generated three times as many customer messages, with AI answering 80% of questions. The company also reported a nearly 50% reduction in nonclinical support tasks such as order updates and general side-effect questions.
The potential advantage is the closed loop connecting intake, treatment, follow-up, and outcomes. HIMS says the platform uses those interactions to improve personalization, identify clinical issues earlier, and help providers match customers with effective treatments. With nearly 3 million subscribers, the company has a large operating dataset. That scale can improve the product if the data is translated into better adherence, retention, and cost-to-serve.
The moat is meaningful but still developing. Brand recognition, customer data, provider workflows, pharmacy operations, and international infrastructure are harder to reproduce than a basic telehealth interface. However, competitors such as Ro, Noom, Teladoc Health (TDOC), BetterHelp, traditional pharmacies, retailers, and large technology companies can attack individual portions of the model.
Operations & Supply Chain
HIMS operates more than 1 million square feet of pharmacy and laboratory testing facilities and has expertise in sterile compounding. Management is also rebuilding customer-flow, product-fulfillment, and catalog-management systems as modular components. That structure should make it easier to add categories and markets, but it also increases the operational burden of quality control across more products and countries.
Scale is beginning to help operations. Management reported three points of sequential leverage in operations and support during Q2, driven by higher pharmacy throughput and early AI savings in customer support. Marketing expense improved to 34% of revenue, down five points year over year and two points sequentially.
Supply concentration remains a risk in specialized and compounded offerings. HIMS has said it is expanding internal manufacturing capabilities and diversifying fulfillment partners. That effort matters because product quality, availability, and regulatory compliance are central to customer trust in prescription healthcare.
Market Analysis
HIMS operates where healthcare services meet consumer technology. One market estimate places global healthcare services at $8.95T in 2025 and $11.32T by 2030, a 4.9% compound annual growth rate. McKinsey has estimated a 9% compound annual growth rate for the broader U.S. healthcare services and technology value pool from 2023 to 2028.
The most attractive pockets are digital access, lower-cost care delivery, workflow automation, and treatment categories with recurring demand. PwC reported that 79% of Gen Z respondents use health technology monthly, including telehealth, online prescriptions, or wearables. That behavior supports HIMS's consumer-first distribution model.
Weight loss is the sector's most visible battleground. Branded GLP-1 medications have attracted pharmaceutical companies, digital health platforms, pharmacies, and wellness providers. HIMS's November 2026 agreement with Eli Lilly expanded access to FDA-approved medicines through the platform, with self-pay pricing beginning at $149 per month for Foundayo and $299 per month for Zepbound.
The market rewards convenience, privacy, and affordability, but those advantages do not eliminate clinical or regulatory standards. HIMS must prove that its consumer acquisition engine can coexist with safe prescribing, reliable fulfillment, and durable retention.
Like what you're reading?
Get full access to AI-powered research reports, market analysis, and portfolio tools.
HIMS serves consumers who value discreet access, online consultations, home delivery, and ongoing support. Its categories include conditions that customers may hesitate to discuss in a traditional setting, such as sexual health, hair loss, mental health, and hormone health. The digital format reduces friction at the first point of care.
The Q2 2026 data shows a customer base becoming more valuable. Subscribers rose 19% year over year, while monthly revenue per average subscriber rose 21% to $92. That combination supports the view that HIMS is increasing both reach and monetization.
The cross-sell model is central. A customer who begins with weight loss can later use laboratory testing, testosterone care, dermatology, or cardiovascular services. Management said five U.S. specialties were operating above a $100M annual run rate and expected testosterone to join that group.
Competitive Landscape
HIMS competes across several layers rather than against one identical public company. Ro and Noom are close consumer-health competitors, especially in weight management. Teladoc and BetterHelp compete in virtual and mental healthcare. Traditional providers, pharmacies, retailers, and large technology companies compete for the same consumer attention and healthcare spending.
HIMS's advantage is breadth. Its platform combines consumer branding, digital consultation, prescription fulfillment, laboratory testing, subscription-style treatment, and several specialties. The company's nearly 3 million subscribers also give it a larger base for cross-selling and data collection than a narrow single-condition provider.
The competitive weakness is that many individual components are contestable. Pharmaceutical companies control branded medicines, pharmacies control distribution, retailers control traffic, and technology companies can invest heavily in digital experiences. HIMS needs its integrated system to produce better retention and lower customer-service costs than those specialized competitors.
Macro & Geopolitical Landscape
Regulation is the dominant external variable. On July 29, 2026, the Federal Trade Commission filed a complaint after nearly three years of cooperation and several months of settlement discussions. HIMS recorded approximately $81M of Q2 nonrecurring acquisition, restructuring, and legal costs, including legal contingency accruals related to the FTC matter.
FDA policy also affects the weight-loss and peptide opportunity. HIMS's planned peptide offering depends on regulatory treatment of compounding and on reliable APIs. The move toward FDA-approved branded medicines through Eli Lilly reduces some compounded-medication exposure, but it also shifts more of the economics toward product pricing and pharmaceutical supply.
International expansion adds country-specific compliance, reimbursement, privacy, and prescribing requirements. The Eucalyptus acquisition extends HIMS across Europe, Australia, and Japan, increasing the addressable customer base while adding integration and currency exposure. The company's 2.5 beta also signals that the stock can amplify broad market moves.
Balance Sheet Health
▌Premium Members Only
Total debt reached $1.38B against $609.8M of cash at June 30, 2026, leaving HIMS with a leveraged balance sheet that limits flexibility if growth slows.
Unlock the full analysis
Premium members get the complete breakdown — pick rationale, financial metrics, and recent earnings detail.
Management lifted full-year 2026 revenue guidance to $3.1B-$3.3B, signaling that subscriber gains and higher revenue per user are still outpacing expectations.
Unlock the full analysis
Premium members get the complete breakdown — pick rationale, financial metrics, and recent earnings detail.
The report’s price framework points to $30 as fair value, with the stock rated Buy because growth, category expansion, and international scale still outweigh the risks.
Unlock the full analysis
Premium members get the complete breakdown — pick rationale, financial metrics, and recent earnings detail.
HIMS is no longer a small telehealth experiment. The company generated $2.35B of revenue in 2025, reached nearly 2.9 million subscribers by Q2 2026, expanded internationally through Eucalyptus, and is building a broader care platform around weight loss, hormone health, laboratory testing, and AI.
The next phase is harder. Q2 net losses, lower gross margins, negative free cash flow, higher debt, the FTC complaint, and insider selling show that growth is carrying a real cost. HIMS must convert scale into durable margins and cash generation while keeping clinical and regulatory execution intact.
For a medium-term investor, the reward is a potential consumer-health platform with multiple growth engines. The discipline is buying only when the price leaves room for the business to make mistakes. At $25.95, the stock earns a Buy rating, with $30.00 as the report's fair-value estimate and a clear need for improving earnings quality.
Why did HIMS margins fall so much?
Gross margin fell to 64% from 76% a year earlier because branded weight-loss products and international revenue carry lower margins than the company’s historical mix. The shift is helping growth, but it is also pressuring profitability and cash conversion in the near term.
+How risky is HIMS's balance sheet?
HIMS carries meaningful balance-sheet risk with $1.38B of total debt versus $609.8M of cash at June 30, 2026. That leverage is manageable if growth stays strong, but it reduces flexibility if execution slips or regulatory costs rise.
+What is driving HIMS's growth?
Growth is being driven by weight loss, sexual health, testosterone, and international expansion, with Q2 revenue reaching $753.2M and subscribers rising to 2.891 million. Monthly revenue per average subscriber also climbed to $92, showing that monetization is improving alongside customer growth.
▌For Active Investors
Want Reports Like This on Any Stock?
Get AI-powered research reports, daily market intelligence, and a personal analyst in your pocket.